At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Closed 10-26 16:00:00 EDT
3.80
+0.10
+2.70%
盘后3.80
+0.000.00%
19:59 EDT
High3.86Low3.64Vol16.10M
Open3.71D1 Closing3.70Amplitude5.95%
Mkt Cap2.27BTradable Cap2.22BTotal Shares598.00M
T/O60.88MT/O Rate2.76%Tradable Shares584.12M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Recursion to Host Webinar on Updated REC-4881 Data for FAP
Reuters  ·  04:06
Recursion to Host Webinar on Updated REC-4881 Data for FAP
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
GlobeNewswire  ·  04:05
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Wall Street’s Risk-Off Reckoning
Bellwether Stocks Movement  ·  10-24 22:11
Wall Street’s Risk-Off Reckoning
Moderna’s Cancer Vaccine Passed Phase 3. What Spooked Investors?
Bellwether Stocks Movement  ·  10-24 12:44
Moderna’s Cancer Vaccine Passed Phase 3. What Spooked Investors?
Recursion Pharmaceuticals Price Target Maintained with a $8.00/Share by Needham
Dow Jones  ·  10-19
Recursion Pharmaceuticals Price Target Maintained with a $8.00/Share by Needham
From $29 To Over $200: Has Moderna Become Dangerously Overvalued?
Bellwether Stocks Movement  ·  10-17
From $29 To Over $200: Has Moderna Become Dangerously Overvalued?
Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.53% in Regular Trading, Stock Offering Dilution Overshadows Sanofi Milestone Progress
Market Focus  ·  10-16
Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.53% in Regular Trading, Stock Offering Dilution Overshadows Sanofi Milestone Progress
Recursion Pharmaceuticals price target raised to $5.90 from $5.30 at Morgan Stanley
TIPRANKS  ·  10-16
Recursion Pharmaceuticals price target raised to $5.90 from $5.30 at Morgan Stanley
Cathie Wood's ARK Reveals Latest Portfolio Moves: Adds More CoreWeave, Buys Nearly $19 Million in Iambic Shares, Trims Amazon and Palantir
Deep News  ·  10-16
Cathie Wood's ARK Reveals Latest Portfolio Moves: Adds More CoreWeave, Buys Nearly $19 Million in Iambic Shares, Trims Amazon and Palantir
Cathie Wood’s ARK Investment buys 4.2M shares of Recursion Pharmaceuticals today
TIPRANKS  ·  10-16
Cathie Wood’s ARK Investment buys 4.2M shares of Recursion Pharmaceuticals today
NASD Most Active Issues
Dow Jones  ·  10-16
NASD Most Active Issues
Recursion Pharmaceuticals Stock (RXRX) Soars 15% on a $10M Milestone Payment from Sanofi
TIPRANKS  ·  10-16
Recursion Pharmaceuticals Stock (RXRX) Soars 15% on a $10M Milestone Payment from Sanofi
Movement Alert｜Recursion Pharmaceuticals, Inc. Intraday Rise 8.42% in Regular Trading, Stock Offering Priced and Sanofi Option Triggers Milestone Payment
Market Focus  ·  10-15
Movement Alert｜Recursion Pharmaceuticals, Inc. Intraday Rise 8.42% in Regular Trading, Stock Offering Priced and Sanofi Option Triggers Milestone Payment
Recursion Prices $200 Million Stock Offering, Sanofi Options Drug Candidate
MT Newswires Live  ·  10-15
Recursion Prices $200 Million Stock Offering, Sanofi Options Drug Candidate
Sanofi Selects Recursion Immunology Drug Candidate for Development
Reuters  ·  10-15
Sanofi Selects Recursion Immunology Drug Candidate for Development
Recursion Pharmaceuticals - Candidate Added to Sanofi Pipeline, Phase 1 Trials Expected in 2027
THOMSON REUTERS  ·  10-15
Recursion Pharmaceuticals - Candidate Added to Sanofi Pipeline, Phase 1 Trials Expected in 2027
Recursion Pharmaceuticals - Receives $10 Mln Milestone Payment, Total Payments NOW $144 Mln
THOMSON REUTERS  ·  10-15
Recursion Pharmaceuticals - Receives $10 Mln Milestone Payment, Total Payments NOW $144 Mln
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
THOMSON REUTERS  ·  10-15
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion Pharmaceuticals - Eligible for over $300 Mln in Additional Milestones and Double Digit Royalties
THOMSON REUTERS  ·  10-15
Recursion Pharmaceuticals - Eligible for over $300 Mln in Additional Milestones and Double Digit Royalties
Recursion Prices $200 Million Stock Offering at $3.25 a Share
Reuters  ·  10-15
Recursion Prices $200 Million Stock Offering at $3.25 a Share

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--